

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5628326

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
EUMEDERIS PHARMACEUTICALS INC.	07/12/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MEDERIS DIABETES INC.
<b>Street Address:</b>	725 LYNWOOD DR.
<b>City:</b>	ENCINITAS
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92024
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	61487636
Application Number:	61487638
Application Number:	61543725
Application Number:	61543721
Patent Number:	10010617
Application Number:	15913845
Application Number:	61728667
Patent Number:	10005817
Application Number:	15986707
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	koren@anderson-IP.com
<b>Correspondent Name:</b>	KOREN ANDERSON
<b>Address Line 1:</b>	7439 NW MOUNTAIN VIEW DR.
<b>Address Line 4:</b>	CORVALLIS, OREGON 97330
<b>ATTORNEY DOCKET NUMBER:</b>	MED001/MED002
<b>NAME OF SUBMITTER:</b>	KOREN ANDERSON
<b>SIGNATURE:</b>	/Koren Anderson/

<b>DATE SIGNED:</b>	07/20/2019
---------------------	------------

**Total Attachments: 4**

source=Exhibit J-1 - Project Springfield - EumederisToMederis\_Assignment (Families 1 & 2)  
[EXECUTED]#page1.tif

source=Exhibit J-1 - Project Springfield - EumederisToMederis\_Assignment (Families 1 & 2)  
[EXECUTED]#page2.tif

source=Exhibit J-1 - Project Springfield - EumederisToMederis\_Assignment (Families 1 & 2)  
[EXECUTED]#page3.tif

source=Exhibit J-1 - Project Springfield - EumederisToMederis\_Assignment (Families 1 & 2)  
[EXECUTED]#page4.tif

**ASSIGNMENT**

WHEREAS, **EuMederis Pharmaceuticals Inc.**, a corporation of the State of Delaware, having a place of business at 12707 High Bluff Dr., Suite 200 San Diego CA 92130 (hereinafter “**Assignor**”) owns the entire right, title and interest in and to the inventions disclosed in and set forth in **Exhibit A** (hereinafter “**Patents and Applications**”);

WHEREAS, **Mederis Diabetes, LLC**, a corporation of the State of Delaware having a place of business at 725 Lynwood Dr., Encinitas, CA 92024, USA (“**Assignee**”) is desirous of acquiring the entire right, title, priority right and interest in and to said Patents and Applications and any Letters Patent or similar legal protection to be obtained for it in the United States and in any and all other countries worldwide.

NOW, THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, in the sum of \$1 USD, the receipt and sufficiency whereof is hereby acknowledged, Assignor have sold, assigned, and transferred, and by these presents do sell, assign and transfer to Assignee, its successors or assigns, the full and exclusive right, title and interest to said Patents and Applications; the right, title and interest for all countries in and to all inventions and improvements disclosed in the aforesaid Patents and Applications, and in and to the said application, all divisions, continuations, continuations-in-part, or renewals thereof, all Letters Patent which may be granted there from, and all reissues or extensions of such patents, and in and to any and all applications which have been or shall be filed in any foreign countries for Letters Patent on the said inventions and improvements, including an assignment of all rights under the provisions of the International Convention, and all Letters Patent of foreign countries which may be granted there from; and I do hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all United States Letters Patent for the aforesaid Patents and Application to the said Assignee as the assignee of the entire right, title and interest in and to the same, for the use of the said Assignee, its successors and assigns.


AND, for the consideration aforesaid, Assignor does hereby agree that Assignor and executors and legal representatives thereof will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said Assignee, its successors and representatives all facts known to Assignor relating to said Patents and Applications and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said Assignee, its successors or assigns the entire right, title and interest in and to said Patents and Applications and the improvement and inventions disclosed in the Patents and Applications, in all countries.

AND, furthermore, Assignor covenants and agrees with said Assignee, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by Assignor and that full right to convey the same as herein expressed is possessed by Assignor.

IN TESTIMONY WHEREOF, I have hereunto set my hand this 12th day of July, 2019.

**Assignor (Conveying Party)**

**EUMEDERIS PHARMACEUTICALS, INC.**

By:   
Name: John F. Nestor, Jr.  
Title: CEO

Assignor Witness Signature: Will Brown


Assignor Witness Name: Will Brown

Date: July 12, 2019

IN TESTIMONY WHEREOF, I have hereunto set my hand this 12th day of July, 2019.

**Assignee (Receiving Party)**

**MEDERIS DIABETES, LLC**

By:   
Name: John F. Nestor, Jr.  
Title: Managing Member

Assignee Witness Signature: Will Brown

Assignee Witness Name: Will Brown

Date: July 12, 2019

**EXHIBIT A**

WSG R Ref. No.	Case Type	Country	App. No.	Filing Date	Patent No.	Issue Date	Title	Status
<b>38617-701.601 Family</b>								
701.105	PRO	US	61/487,636	18-May-2011			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Expired
701.106	PRO	US	61/487,638	18-May-2011			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Expired
701.108	PRO	US	61/543,725	05-Oct-2011			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Expired
701.109	PRO	US	61/543,721	05-Oct-2011			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Expired
701.601	PCT	PCT	PCT/US2012/038429	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	30 MO DONE
701.831	PCT	US	14/118,546	18-Nov-2013	10,010,617	03-Jul-2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.301	CON	US	15/913,845	06-Mar-2018			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Allowed
701.611	PCT	EP	12784971.9	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.6111	DIV	EP	EP19176297.0	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.681	PCT	AU	2012255116	17-May-2012	2012255116	07-Sep-2017	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.6811	DIV	AU	2017216533	12-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.701	PCT	CA	2,836,573	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.711	PCT	CN	201280035528.1	17-May-2012	ZL201280035528.1	06-Jul-2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.7111	DIV	CN	201810595590.5	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.741	PCT	IN	9253/CHENP/2013	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.761	PCT	JP	2014-511553	17-May-2012	6148228	26-May-2017	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.7611	DIV	JP	2017-008902	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.771	PCT	KR	10-2013-7033672	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.891	RCN	HK	14109765.8	17-May-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Allowed

38617-701.602 Family								
701.11 1	PRO	US	61/728,667	20-Nov-2012			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Expired
701.60 2	ORD	WO	PCT/US2013/071 067	20-Nov-2013			IMPROVED POLYPEPTIDE PHARMACEUTICALS	30 MO DONE
701.83 2	PCT	US	14/646,246	20-May-2015	10,005,817	26-Jun- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.30 2	CON	US	15/986,707	22-May-2018			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.61 2	PCT	EP	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.62 1	EPP	DE	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.63 1	EPP	FR	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.64 1	EPP	GB	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.65 1	EPP	BE	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.65 3	EPP	CH	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.65 6	EPP	DK	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.66 2	EPP	IE	13857269.8	20-Nov-2013	2922877	05-Sep- 2018	IMPROVED POLYPEPTIDE PHARMACEUTICALS	Granted
701.61 21	DIV	EP	18183208.0	20-Nov-2013			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending
701.70 2	PCT	CA	2,891,929	20-Nov-2013			IMPROVED POLYPEPTIDE PHARMACEUTICALS	Pending